Welcome to our dedicated page for Adlai Nortye Ltd. news (Ticker: ANL), a resource for investors and traders seeking the latest updates and insights on Adlai Nortye Ltd. stock.
Adlai Nortye Ltd. (NASDAQ: ANL) is a global clinical-stage biotechnology company focused on targeted and immune-modulating cancer therapies, and its news flow reflects active development across a multi-asset oncology pipeline. Company announcements highlight progress in clinical trials, preclinical research, licensing arrangements and corporate governance, giving investors and observers insight into how its programs are advancing.
Recent news releases describe updates on Buparlisib (AN2025), an oral pan-PI3K inhibitor in the BURAN phase 3 trial for recurrent or metastatic head and neck squamous cell carcinoma, as well as clinical and preclinical data for AN4005, AN8025, AN9025, AN4035 and AN0025. Adlai Nortye regularly reports on presentations at major scientific meetings such as AACR, AACR-NCI-EORTC and ASCO, where it shares data on its PD-L1 inhibitor, tri-specific fusion protein, pan-RAS(ON) inhibitor, CEACAM5-targeting ADC and EP4 antagonist in various tumor settings.
Company news also covers business developments, including an exclusive license agreement granting ASK Pharm rights to develop, manufacture and commercialize AN9025 in a defined Greater China territory, and updates on partnerships with organizations such as Cancer Research UK’s Clinical Trials Unit. Governance-related releases include board appointments, committee changes and the adoption of a 2025 Share Incentive Plan.
By following ANL news, readers can monitor key milestones such as trial initiations and expansions, conference presentations, licensing deals, share incentive plan approvals and changes in board composition. This news page aggregates those disclosures in one place so users can review how Adlai Nortye’s oncology programs and corporate activities are evolving over time.
Adlai Nortye announced the dosing of the first patient in its Phase II clinical trial, named ARTEMIS, for palupiprant (AN0025) in treating locally advanced rectal cancer. This study, led by the Cancer Research UK Clinical Trials Unit at the University of Leeds, aims to compare total neoadjuvant therapy (TNT) with or without AN0025 in patients with moderate to high-risk rectal cancer. The trial involves 140 patients, divided into two groups, and will evaluate clinical complete response (cCR) rate six months post-radiotherapy. The trial builds on encouraging Phase Ib results and seeks to improve efficacy while minimizing invasive surgeries.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.